STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

STOK Form 4: CMO Barry Ticho disposes 5,343 shares via 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics insider sale executed under a pre-established plan. Chief Medical Officer Barry Ticho sold 5,343 shares of common stock on 10/01/2025 at a weighted average price of $23.6414, with sale prices ranging from $23.40 to $24.08. After the transactions the reporting person beneficially owned 13,126 shares. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024, and the Form 4 was signed via attorney-in-fact on 10/03/2025.

Positive

  • Transaction executed under a Rule 10b5-1 plan adopted on 12/11/2024, indicating pre-authorized trading
  • Filing discloses exact sale range ($23.40 to $24.08), which improves transparency

Negative

  • Insider sold 5,343 shares, reducing beneficial ownership to 13,126
  • Sale involved multiple transactions, which may prompt investor questions about timing or size

Insights

Insider sale followed a pre-set trading plan; shows compliance, not necessarily new company information.

The filing documents a Rule 10b5-1 plan sale of 5,343 shares by the Chief Medical Officer on 10/01/2025 at a weighted average price of $23.6414.

This matters because 10b5-1 plans are designed to separate timing decisions from insider knowledge, indicating the trades were pre-authorized on 12/11/2024 rather than reactive to recent undisclosed events.

Insider Ticho Barry
Role CHIEF MEDICAL OFFICER
Sold 5,343 shs ($126K)
Type Security Shares Price Value
Sale Common Stock 5,343 $23.6414 $126K
Holdings After Transaction: Common Stock — 13,126 shares (Direct)
Footnotes (1)
  1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.08 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Ticho Barry
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 S(1) 5,343 D $23.6414(2) 13,126 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.08 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jonathan Allan, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the Stoke Therapeutics (STOK) Form 4 disclose?

The Form 4 shows Chief Medical Officer Barry Ticho sold 5,343 shares on 10/01/2025 at a weighted average price of $23.6414 under a Rule 10b5-1 plan.

How many shares does the reporting person own after the sale?

After the reported transactions the reporting person beneficially owned 13,126 shares.

Were these sales part of a trading plan?

Yes. The filing states the sales were executed pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024.

What price range were the shares sold at?

The shares were sold in multiple transactions at prices ranging from $23.40 to $24.08, with a weighted average of $23.6414.

Who signed the Form 4?

The Form 4 was signed by Jonathan Allan, Attorney-in-Fact on 10/03/2025.